Proteasome Inhibitor News and Research

RSS

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.

7 Jun 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology in Chicago, IL from June 4-8.

4 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March.

18 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists led by researchers from Weill Cornell Medical College has identified compounds that inhibit that mechanism -- without damaging human cells.

17 Sep 2009

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.

26 Jun 2008

Velcade, lenalidomide and dexamethasone combo show promise for multiple myeloma

A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

13 Dec 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

25 Sep 2007

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented in Atlanta, Georgia at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

20 Sep 2007

Novel targeted therapy effectively treats acute leukemia

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.

20 Apr 2007

Proteasome Inhibitor News and Research

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Findings may lead to drugs that destroy TB in dormant stage of lifecycle

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

Velcade, lenalidomide and dexamethasone combo show promise for multiple myeloma

Lenalidomide - dexamethasone combination effective against multiple myeloma

Some cancer cells mimic stem cells to evade chemotherapy

Some cancer cells mimic stem cells to evade chemotherapy

Novel targeted therapy effectively treats acute leukemia

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News